The estimated Net Worth of Mark G Foletta is at least $9.87 millió dollars as of 17 June 2024. Mr. Foletta owns over 6,000 units of Dexcom Inc stock worth over $3,861,571 and over the last 12 years he sold DXCM stock worth over $5,633,930. In addition, he makes $370,568 as Lead Independent Director at Dexcom Inc.
Mark has made over 35 trades of the Dexcom Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 6,000 units of DXCM stock worth $702,000 on 17 June 2024.
The largest trade he's ever made was buying 10,000 units of Dexcom Inc stock on 13 August 2015 worth over $76,400. On average, Mark trades about 1,161 units every 48 days since 2013. As of 17 June 2024 he still owns at least 56,398 units of Dexcom Inc stock.
You can see the complete history of Mr. Foletta stock trades at the bottom of the page.
Mark G. Foletta CPA serves as Lead Independent Director of the Company. He has served on our Board since November 2014 and has served as our Lead Independent Director since November 2015. Mr. Foletta has been the Chief Financial Officer and Executive Vice President of Tocagen, Inc., a publicly-traded biotech company, since February 2017. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from March 2006 through Amylin’s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Prior to joining Amylin in 2000, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst & Young. Mr. Foletta is currently a member of the Board of Directors and Audit Committee of AMN Healthcare Services, Inc., a publicly traded healthcare workforce solutions provider. From August 2015 to July 2016, Mr. Foletta served as the interim CFO of Biocept, Inc., an early commercial-stage publicly traded molecular oncology diagnostics company. Mr. Foletta is also on the Board of Directors of Viacyte, Inc., a private biotechnology company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara and is a member of the Corporate Directors Forum.
As the Lead Independent Director of Dexcom Inc, the total compensation of Mark Foletta at Dexcom Inc is $370,568. There are 9 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.
Mark Foletta is 59, he's been the Lead Independent Director of Dexcom Inc since 2015. There are 11 older and 17 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
Mark's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff és Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: